Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
In response to the increasing prevalence of leukemia, ineffective conventional treatments, and poor prognosis, researchers are developing new drugs. High-throughput screening (HTS) is gaining attention. Alfa Cytology offers a HTS platform for rapid screening of leukemia drugs. We provide diverse services, phenotypic screening, and customized plans to help identify effective compounds from large drug libraries.
Two main approaches in drug discovery are target-based development and phenotypic screening. Early leukemia drugs were not target-based but used for other diseases. High-throughput screening (HTS) analyzes activities of many compounds. HTS is widely used in early leukemia drug discovery, offering insights for targeted therapy and development.
Fig. 1. A typical high-content screening workflow. (Blay, V. et al., 2020)
The main goal of HTS is that through compound library screening, a large number of chemical or biological compounds can be automatically tested to identify candidate compounds that affect the target in the desired way. Alfa Cytology provides comprehensive high-throughput drug screening services, including but not limited to the following.
With a vast collection of in-house compounds exceeding one million, we offer extensive high-throughput screening services. Our proficient team in drug discovery, along with state-of-the-art platforms and diverse compound libraries, aims to provide an optimal foundation for novel research endeavors.
The disease model developed for HTS helps to improve the success of HTS screening. We have various models for leukemia drug development to support the screening of candidate compounds.
We provide high-throughput drug screening techniques to screen possible drug candidates by using cell viability assays. Compound libraries include key bioactivity libraries, natural product libraries, fragment libraries, and diversity sets to increase hit rates and find candidate compounds.
The application of high-throughput technology to genomics, epigenomics, transcriptomics, proteomics, and metabonomics can provide in-depth and reliable data and lead to the rapid discovery of drugs for leukemia.
| Methods | Service Details |
|---|---|
| Genomics | We offer next-generation sequencing (NGS), which allows you to ask the entire genome faster. Predict possible drugs from genomic information. |
| Proteomics | We provide high-throughput proteomics techniques: mass spectrometry (MS) and antibody-based reversed-phase protein array (RPPA), which can distinguish protein subtypes, post-translational modifications, and amino acid changes, and screen possible drug targets. |
| Metabolomics | The metabonomic analysis we provide reveals the metabolic spectrum of leukemia, which can be used for drug discovery and targeted therapy. |
Alfa Cytology is a drug discovery service company that provides high-throughput drug screening services. We have a wealth of experience and expertise in high-throughput screening of leukemia drugs. We focus on the different needs of our customers, provide a large number of selected compounds, and customize the test design of HTS. If you are interested in our services or would like to know more, please contact us.
Reference